Newsroom | 48653 results

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS’ thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%. These threshold...

LAUSANNE, Switzerland--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its review of safety data from the Phase I dose escalation portion of the STARLIGHT-1 trial. Based on the favorable safety profile observed, the DSMB recommen...

CARLSBAD, Calif.--(BUSINESS WIRE)--Arima Genomics, a company leveraging whole-genome sequence and structure information, today announced new data to be presented at ASH....

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade Plasmid DNA Preps designed to support the advancement of pharmaceutical and biotech customers’ pre-clinical studies. “Our new plasmid preps combine the quality and consistency needed for preclinical research with the speed and cost efficiency customers have come to expect from Twist,” said Emily M. Leproust, CEO and co-founder of Tw...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company will present and participate in the Sachs Associates 9th Annual Neuroscience Innovation Forum on January 11, 2026 during “J.P. Morgan Week 2026” in San Francisco. Additionally, Enveric will attend Biotech Showcase 2026, which is b...

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH) (NeuPath or the “Company”) announced today that the TSX Venture Exchange (the “Exchange”) has accepted a notice filed by NeuPath of its intention to renew its normal course issuer bid (“NCIB”). Under the NCIB, the Company may, during the 12-month period commencing December 4, 2025 and ending December 3, 2026 (or on such date that the Company completes its purchases or provides notice of termination), purchase up to 2,527,224 common share...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new benchmark in tubeless diabetes technology by offering a lower 100 mg/dL Target Glucose option and a more seamless automated experie...

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to present at 2025 RBC Capital Markets Healthcare Private Company Conference and participate in one-on-one meetings....

DURHAM, N.C.--(BUSINESS WIRE)--FDA approves expanded indication for MED-EL cochlear implants for children seven months and older with bilateral sensorineural hearing loss....